ESR1 and breast cancer: In the first study we identified patients from two very different groups of patients (ER(+)/modified Scarff-Bloom-Richardson (mSBR1) and ER(−)/mSBR3) in our breast cancer database and tumor bank and assessed for WAVE3 expression levels in the primary tumors using IHC.